Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD

At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  

Continue reading

Tucatinib Plus Trastuzumab Approved for Colorectal Cancer

The FDA has granted accelerated approval to tucatinib (Tukysa®, Seagen, Inc.) with trastuzumab for rat sarcoma (RAS) wild-type human epidermal growth factor receptor 2 (HER2)–positive unresectable or metastatic colorectal cancer (CRC) that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. "Patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer receive limited clinical benefit with currently available therapies," said John Stric...

Continue reading

Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD

Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  

Continue reading

Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD

Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  

Continue reading

Addressing Knowledge Gaps in the Treatment of Metastatic Colorectal Cancer

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...

Continue reading

Guiding Colorectal Cancer Treatment Decisions by Using ctDNA With Jeanne Tie, MD, MBChB, FRACP

At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.  

Continue reading

Providing Proficiency for Personalized Care Plans for Metastatic Colorectal Cancer

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone, making CRC the third most commonly diagnosed cancer in the United States. If found early, CRC can be and is often cured, with a 5-year survival rate ...

Continue reading

Treatment Options for Patients with Metastatic Colorectal Cancer: Jaffer A. Ajani, MD

Colorectal cancer is the third leading cause of cancer death among men and women in the United States. Each year, there are 149,500 new cases of colorectal cancer, and 52,980 people die from the disease. Treatment choice depends on many factors, including patient characteristics, tumor characteristics, molecular characteristics, and patient preferences. Approximately 21% of patients present with metastatic disease, which has a five-year survival rate of only 14%. Results from the CRYSTAL and PRI...

Continue reading

Challenges and New Developments in Metastatic Colorectal Cancer With Tanios Bekaii-Saab, MD

Despite the many obstacles associated with treating and managing patients with metastatic colorectal cancer, the ongoing study of several novel agents has the potential to significantly improve the outcomes of these patients in the coming years. In this interview, Tanios Bekaii-Saab, MD, Professor of Medicine at the Mayo Clinic Cancer Center in Phoenix, Arizona, discusses strategies to optimize the management of metastatic colorectal cancer and the promising developments which may advance treatm...

Continue reading

Colorectal Cancer Surgery: Still Safe During the Pandemic

According to a new study, patients undergoing surgery for colorectal cancer experienced a low rate of COVID-19 infection during the postoperative period, suggesting that colorectal cancer surgery can be performed with minimal risks during the pandemic. "With the COVID-19 pandemic, the management of patients with cancer has been significantly impacted, from diagnosis to follow-up, leading to a proposal of treatment strategy adaptations," write the investigators of the COVID-GRECCAR study, led by ...

Continue reading

For Patients With Metastatic Colorectal Cancer, Diet Does Not Improve Survival

Diet quality did not improve overall survival in patients with metastatic colorectal cancer (mCRC), according to a prospective cohort study published today in JAMA Network Open. The investigators, led by Erin Van Blarigan, Scd, Assistant Professor of Epidemiology & Biostatistics and of Urology at the University of California, San Francisco, evaluated the diet qualities of 1,284 patients with metastatic colorectal cancer from October 2005 to February 2012. The patients were enrolled into Canc...

Continue reading

Cancer Overscreening in Older Adults: Jennifer L. Moss, PhD

According to a study recently published in JAMA Network Open, a high proportion of older adults with average cancer risk are overscreened for colorectal, cervical, and breast cancers after surpassing specified upper age limits recommended by the US Preventive Services Task Force (USPSTF). In this interview, Jennifer L. Moss, PhD, first author of the study, discusses the significance of these findings, explains the risks of overscreening, and shares advice for reducing overscreening among older a...

Continue reading

Cancer Overscreening High Among Older Adults

Overscreening for colorectal, cervical, and breast cancer is prevalent among older adults in the United States, according to the results of a new study. While routine cancer screening for adults with average cancer risk is recommended by the US Preventive Services Task Force (USPSTF), it is recommended that screening be discontinued once individuals reach a specified upper age limit, defined as age 75 for colorectal cancer, age 65 for cervical cancer, and age 74 for breast cancer. However, many ...

Continue reading

Hypertensive Medications and Reduced Colorectal Cancer Risk: Wai K. Leung, MD

In this interview, Wai K. Leung, MD, speaks with i3 Health about his research team's finding, recently published in Hypertension, that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with a decreased risk of colorectal cancer within three years of colonoscopy. Dr. Leung discusses the significance of the study's results and shares potential reasons behind the link between ACE inhibitor and ARB use and reduced colorectal cancer risk. Can you c...

Continue reading

Colorectal Cancer: Common Blood Pressure Medications May Reduce Risk

Taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with a decreased risk of colorectal cancer within three years of colonoscopy, according to the results of a new study. By inhibiting or blocking angiotensin, a protein that raises blood pressure by constricting the arteries, ACE inhibitors and ARBs treat heart disease, heart failure, and high blood pressure. Whether ACE inhibitors and ARBs can also play a role in cancer prevention, howeve...

Continue reading

Noninvasive Nanoscale Test Accurately Detects Bladder Cancer

Researchers have developed an accurate, noninvasive diagnostic test that can be used for a number of cancers. Their success in applying this test to the detection of bladder cancer makes it the first to effectively utilize atomic force microscopy (AFM) for diagnostic purposes. Bladder cancer is one of the most common cancers and one of the most common causes of cancer-related death. If it is detected in stage 0, bladder cancer has a five-year survival rate of 98%; if it is detected at an advance...

Continue reading

Family History-Based Colorectal Cancer Screening: Samir Gupta, MD

Colorectal cancer rates in younger adults are currently rising, and those with a family history of the disease face an even greater risk. Samir Gupta, MD, Chief of the Gastrointestinal (GI) Section of the San Diego Veterans Affairs Healthcare System, recently spoke with i3 Health about his research team's finding, now published in Cancer, that only 25% of patients between the ages of 40 to 49 who were diagnosed with colorectal cancer as a result of screening met the family history-based early sc...

Continue reading

Encorafenib/Cetuximab for BRAF V600E–Mutant Metastatic Colorectal Cancer: Scott Kopetz, MD, PhD, FACP

After patients with metastatic colorectal cancer who have a BRAF V600E mutation stop responding to first-line treatment, they have a median survival of only four to six months. These patients now have a new option in a combination therapy consisting of encorafenib (Braftovi®, Array BioPharma) and cetuximab (Erbitux®, Lilly), which was approved by the FDA earlier this month for adults with previously treated BRAF V600E-mutated metastatic colorectal cancer. In this interview with i3 Health, Scott ...

Continue reading

Family History-Based Screening Improves Colorectal Cancer Detection

In individuals with a family history of colorectal cancer, early screening improves detection, leading to a better prognosis in younger patients with this condition. Colorectal cancer rates in adults under the age of 50 are currently on the rise, and individuals with a family history of the disease face an even higher risk than the general population. Several societies, including the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiol...

Continue reading

BRAF V600E-Mutant Colorectal Cancer: Triplet and Doublet Therapies Improve Quality of Life

An updated analysis of a phase 3 trial reports that encorafenib/cetuximab, alone or in combination with binimetinib, improves quality of life compared with the current standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer whose disease progressed after one or two prior therapies. The BEACON CRC study, the results of which were published in the New England Journal of Medicine in October, investigated the efficacies of encorafenib/cetuximab/binimetinib (triplet therapy) ...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.